Skip to main content

Prostate Cancer

Edited by: Suneil Jain and Helen McCarthy

Prostate cancer is the most commonly diagnosed cancer in men. Localized disease is commonly treated with androgen deprivation therapy, surgery or radiotherapy but currently many men develop metastatic castrate resistant prostate cancer.

Novel approaches for early diagnosis and improved therapy are required. This series in Cancer Nanotechnology provides a collection of original papers and expert reviews covering a broad range of nanomedical approaches to improving outcomes in prostate cancer.

Nanoparticles have enormous potential to act as radiosensitizers, and targeted therapies are being refined for clinical use with the potential to enhance image guided radiotherapy. Furthermore, many nanoparticles have been designed as drug delivery agents with the promise of delivering increased therapeutic payloads directly to the tumor.

New articles in the series will be added here as they are published.

  1. Review

    DNA vaccination for prostate cancer: key concepts and considerations

    While locally confined prostate cancer is associated with a low five year mortality rate, advanced or metastatic disease remains a major challenge for healthcare professionals to treat and is usually terminal....

    Grace Cole, Joanne McCaffrey, Ahlam A. Ali and Helen O. McCarthy

    Cancer Nanotechnology 2015 6:2

    Published on: 2 July 2015